Floatz logo

Dexasone

Cancer Of Unknown Primary Site

Alliance for Clinical Trials in OncologySmall moleculePhase 3Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Cancer Of Unknown Primary Site cohort.

Asset / SponsorPhaseRating
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
Etoposide
University of California, Davis
Phase 2/3BBB
NOGITECAN
National Cancer Institute (NCI)
Phase 2BBB
Sargramostim
Barbara Ann Karmanos Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

Dexasone is also rated in:

chemotherapy-induced toxicityActive
A
Indicative · Phase 4
82 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →